Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19.

ABSTRACT:

Importance

Data describing the early additional protection afforded by the recently recommended BNT162b2 XBB vaccine (Pfizer-BioNTech; 2023-2024 formulation) are limited.

Objective

To estimate the association between receipt of the BNT162b2 XBB vaccine and medically attended COVID-19 outcomes among US adults 18 years and older.

Design, setting, and participants

This test-negative case-control study was performed to estimate the effectiveness of the BNT162b2 XBB vaccine against COVID-19-associated hospitalization and emergency department (ED) or urgent care (UC) encounters among adults in the Kaiser Permanente Southern California health system between October 10, 2023, and December 10, 2023. Cases were those presenting with an acute respiratory illness and who had a po

SUBMITTER: Tartof SY 

PROVIDER: S-EPMC11197441 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature